What Should Investors Make Of Conflicting Results Surrounding Gilead's Remdesivir?
Sat May 02, 2020 5:53 pm
What Should Investors Make Of Conflicting Results Surrounding Gilead's Remdesivir?
David Jagielski
(TMFdjagielski)
May 2, 2020 at 5:40AM
How well Gilead Sciences (NASDAQ:GILD) does this year will inevitably depend on how effective the company's antiviral drug, remdesivir, is in treating COVID-19. If the drug proves to be a flop, the stock will fall from where it is today. However, if the treatment is effective and widespread adoption looks imminent, then Gilead's stock is likely headed skyward, hitting new all-time highs along the way.
Unfortunately, thus far, there have been conflicting results surrounding whether the drug can help COVID-19 patients. Let's take a closer look at the remdesivir results and what they mean for investors to decide whether the stock is a buy or not.
On April 23, the results of a remdesivir study in China were released to the public. And although the study didn't have enough patients to be completed, the initial results showed that for adults with severe COVID-19, remdesivir "was not associated with clinical or virological benefits." After one month, 13.9% of patients who received remdesivir died compared to 12.8% of patients in the control arm.
Gilead discounted the results. The company's spokesperson Amy Flood said the study "had too few patients" to be meaningful; just 158 patients took redesivir and 79 patients in the control group. The company also said the data suggested the drug had a potential benefit if patients used it in the early stages of COVID-19.
Image source: Getty Images.
But not even a week later, on April 29, the National Institute of Allergy and Infectious Diseases (NIAID) released data from its study which indicated more positive results for remdesivir. The study involved 1,063 patients and the results showed that using remdesivir led to quicker recovery times. Patients with COVID-19 who took remdesivir had a median recovery time of 11 days compared to 15 days for those who took the placebo. The mortality rate of 8% in the remdesivir group was also lower than the 11.6% of patients in the control group who died.
NIAID's head Dr. Anthony Fauci said, "the data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery" and that "what it has proven is that a drug can block this virus."
Investors should disregard the study from China because the sample size is much smaller than the one from the NIAID, and it would be difficult to gain any strong conclusions from that data. COVID-19 has proven to be a volatile and unpredictable disease. Some people with COVID-19 have shown no symptoms, while others require hospitalization and in extreme cases, ventilators. Due to the disease's complexity, a large sample size is needed to get a good cross-section of patients and more balanced results.
What's disappointing isn't that the Chinese study showed no improvement but that the results from the NIAID were not definitive in showing that remdesivir stopped the virus. While the median recovery time did improve by four days, it's not the slam dunk that investors may have been hoping for to say that remdesivir can stop COVID-19 in its tracks and that it can completely prevent fatalities. But at the very least, the study was positive, and there's hope that remdesivir can reduce hospitalizations and deaths from the disease.
The good news is that there will be a lot more data coming in the weeks ahead that will provide more insight into the drug's effectiveness. On Friday, the Food and Drug Administration gave remdesivir emergency use authorization so that it can be used to treat patients with severe COVID-19, which the agency defined as "patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator."
With more patients now able to access remdesivir, it will help give medical professionals more insight into how the drug works and which scenarios it's effective and in which it's not. And that can go a long way in arriving at some more definitive conclusions as to how useful remdesivir can be in the fight against COVID-19.
The key takeaway from the results thus far is that it's just too early to tell whether remdesivir will be a success in the battle against the coronavirus. As more patients are treated with remdesivir, there'll be more clarity as to which situations it works best in and which it doesn't. There's still a lot of optimism that remdesivir can help treat COVD-19 patients, and there's potential to make the stock one of the hottest buys of 2020.
But even without remdesivir, Gilead's still a good dividend stock to own. It pays a quarterly dividend of $0.68, which yields 3.4% annually -- more than you'd earn from the average S&P 500 stock that pays just 2% per year. Gilead's stock is up around 25% this year, as it has also outperformed the index this year, which is down 12%.
At a price-to-earnings ratio of 18, Gilead isn't a terribly risky buy today, even if remdesivir fails to live up to the hype. The company's been a safe bet to post a profit as it's been in the black in each of the past 10 years. In the past two years, its profit margin has been a very healthy 24% of revenue.
Gilead released its first-quarter results of 2020 on April 30, which showed revenue growth of 5% from the prior-year period. And although the company's net income was down by 21% from where it was a year ago, that was largely due to higher taxes and other expenses; Gilead's operating income was 7% higher than Q1 2019.
Overall, there are good reasons to invest in the healthcare stock even without remdesivir, and that's why Gilead's still an attractive buy even if the drug fails. And if it succeeds, the sky's the limit for Gilead.
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The Motley Fool Makes 5G Buy Alert
5G is one of the greatest arrivals in technology since the birth of the internet.
And in 2020… we could see an onslaught of new wealth-building opportunities that would potentially dwarf any that came before them.
There’s a perfect storm being created by some of the biggest tech titans in the world… with each one fighting tooth and nail to win the 5G arms race.
But the smart money is doing something different…
Fortunately, our team at Motley Fool Rule Breakers has identified one under-the-radar California company that’s cleverly positioned itself to dominate the 5G industry with its unique business model and technology.
Simply click here to get the full story now.
There's a lot riding on the success of the company's potential treatment for COVID-19.
David Jagielski
(TMFdjagielski)
May 2, 2020 at 5:40AM
How well Gilead Sciences (NASDAQ:GILD) does this year will inevitably depend on how effective the company's antiviral drug, remdesivir, is in treating COVID-19. If the drug proves to be a flop, the stock will fall from where it is today. However, if the treatment is effective and widespread adoption looks imminent, then Gilead's stock is likely headed skyward, hitting new all-time highs along the way.
Unfortunately, thus far, there have been conflicting results surrounding whether the drug can help COVID-19 patients. Let's take a closer look at the remdesivir results and what they mean for investors to decide whether the stock is a buy or not.
Here's how the data has shaken out
On April 23, the results of a remdesivir study in China were released to the public. And although the study didn't have enough patients to be completed, the initial results showed that for adults with severe COVID-19, remdesivir "was not associated with clinical or virological benefits." After one month, 13.9% of patients who received remdesivir died compared to 12.8% of patients in the control arm.
Gilead discounted the results. The company's spokesperson Amy Flood said the study "had too few patients" to be meaningful; just 158 patients took redesivir and 79 patients in the control group. The company also said the data suggested the drug had a potential benefit if patients used it in the early stages of COVID-19.
Image source: Getty Images.
But not even a week later, on April 29, the National Institute of Allergy and Infectious Diseases (NIAID) released data from its study which indicated more positive results for remdesivir. The study involved 1,063 patients and the results showed that using remdesivir led to quicker recovery times. Patients with COVID-19 who took remdesivir had a median recovery time of 11 days compared to 15 days for those who took the placebo. The mortality rate of 8% in the remdesivir group was also lower than the 11.6% of patients in the control group who died.
NIAID's head Dr. Anthony Fauci said, "the data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery" and that "what it has proven is that a drug can block this virus."
Why the results may be a little disappointing
Investors should disregard the study from China because the sample size is much smaller than the one from the NIAID, and it would be difficult to gain any strong conclusions from that data. COVID-19 has proven to be a volatile and unpredictable disease. Some people with COVID-19 have shown no symptoms, while others require hospitalization and in extreme cases, ventilators. Due to the disease's complexity, a large sample size is needed to get a good cross-section of patients and more balanced results.
What's disappointing isn't that the Chinese study showed no improvement but that the results from the NIAID were not definitive in showing that remdesivir stopped the virus. While the median recovery time did improve by four days, it's not the slam dunk that investors may have been hoping for to say that remdesivir can stop COVID-19 in its tracks and that it can completely prevent fatalities. But at the very least, the study was positive, and there's hope that remdesivir can reduce hospitalizations and deaths from the disease.
More definitive answers could be coming soon
The good news is that there will be a lot more data coming in the weeks ahead that will provide more insight into the drug's effectiveness. On Friday, the Food and Drug Administration gave remdesivir emergency use authorization so that it can be used to treat patients with severe COVID-19, which the agency defined as "patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator."
With more patients now able to access remdesivir, it will help give medical professionals more insight into how the drug works and which scenarios it's effective and in which it's not. And that can go a long way in arriving at some more definitive conclusions as to how useful remdesivir can be in the fight against COVID-19.
Should investors buy Gilead?
The key takeaway from the results thus far is that it's just too early to tell whether remdesivir will be a success in the battle against the coronavirus. As more patients are treated with remdesivir, there'll be more clarity as to which situations it works best in and which it doesn't. There's still a lot of optimism that remdesivir can help treat COVD-19 patients, and there's potential to make the stock one of the hottest buys of 2020.
But even without remdesivir, Gilead's still a good dividend stock to own. It pays a quarterly dividend of $0.68, which yields 3.4% annually -- more than you'd earn from the average S&P 500 stock that pays just 2% per year. Gilead's stock is up around 25% this year, as it has also outperformed the index this year, which is down 12%.
At a price-to-earnings ratio of 18, Gilead isn't a terribly risky buy today, even if remdesivir fails to live up to the hype. The company's been a safe bet to post a profit as it's been in the black in each of the past 10 years. In the past two years, its profit margin has been a very healthy 24% of revenue.
Gilead released its first-quarter results of 2020 on April 30, which showed revenue growth of 5% from the prior-year period. And although the company's net income was down by 21% from where it was a year ago, that was largely due to higher taxes and other expenses; Gilead's operating income was 7% higher than Q1 2019.
Overall, there are good reasons to invest in the healthcare stock even without remdesivir, and that's why Gilead's still an attractive buy even if the drug fails. And if it succeeds, the sky's the limit for Gilead.
10 stocks that could be the biggest winners of the stock market crash
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 16, 2020
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The Motley Fool Makes 5G Buy Alert
5G is one of the greatest arrivals in technology since the birth of the internet.
And in 2020… we could see an onslaught of new wealth-building opportunities that would potentially dwarf any that came before them.
- Bigger than the dot-com boom
- Bigger than the Bitcoin boom of 2017
- Bigger than pot stocks
There’s a perfect storm being created by some of the biggest tech titans in the world… with each one fighting tooth and nail to win the 5G arms race.
But the smart money is doing something different…
Fortunately, our team at Motley Fool Rule Breakers has identified one under-the-radar California company that’s cleverly positioned itself to dominate the 5G industry with its unique business model and technology.
Simply click here to get the full story now.
- Scientists want to see the evidence that shows remdesivir works for Covid-19
- Coronavirus: US authorises use of anti-viral drug Remdesivir
- Remdesivir could help end coronavirus lockdown despite failure of Chinese trials, scientists say
- Remdesivir: The Covid-19 drug helping patients recover faster
- Remdesivir: the antiviral drug is being touted as a possible coronavirus treatment – but will it work?
Permissions in this forum:
You cannot reply to topics in this forum
|
|